Caitlin M. Bair


Thank you for your interest. Before you communicate with one of our attorneys, please note: Any comments our attorneys share with you are general information and not legal advice. No attorney-client relationship will exist between you or your business and O’Melveny or any of its attorneys unless conflicts have been cleared, our management has given its approval, and an engagement letter has been signed. Meanwhile, you agree: we have no duty to advise you or provide you with legal assistance; you will not divulge any confidences or send any confidential or sensitive information to our attorneys (we are not in a position to keep it confidential and might be required to convey it to our clients); and, you may not use this contact to attempt to disqualify O’Melveny from representing other clients adverse to you or your business. By clicking "accept" you acknowledge receipt and agree to all of the terms of this paragraph and our Disclaimer.

Caitlin Bair, Managing Partner of O’Melveny’s San Francisco office, is a highly skilled litigator who represents clients in the biologics, pharmaceutical, medical device, and managed care industries. She expertly counsels Fortune 500 companies and audit committees in internal investigations in response to high-stakes federal and state enforcement inquiries and derivative lawsuits.


  • Spanish

Honors & Awards

  • Recommended by The Legal 500 US for Healthcare: Health Insurers (2022)
  • Named to the 40 & Under Hot List in Health Care & White Collar Crime by Benchmark Litigation (2018-2020)


Bar Admissions

  • California
  • Indiana

Court Admissions

  • US Court of Appeals, Ninth Circuit
  • US District Court, Central and Northern Districts of California


  • University of Michigan, J.D., cum laude; Articles Editor, Michigan Law Review; Finalist, Henry M. Campbell Moot Court Competition; Recipient, Irving Stenn, Jr., Award
  • Yale University, B.A., History, honors

Professional Activities


  • Honorable Ronald M. Gould, US Court of Appeals, Ninth Circuit


  • “Is Sorrell the Death Knell for FDA’s Off-Label Marketing Restrictions?” Journal of Health & Life Sciences Law (Feb. 2012)
  • Defending an international biotechnology manufacturer in a qui tam False Claims Act investigation into kickback and off-label allegations (the U.S. Department of Justice declined to intervene and the qui tam plaintiff dismissed the case with prejudice)
  • Defending medical device manufacturer against allegations of consumer protection act violations brought by state attorneys general
  • Defending a national managed care organization in a qui tam False Claims Act investigation into compliance with Medicare Advantage regulations, including allegations related to inflated premiums resulting from inaccurate risk-adjustment submissions
  • Defending major technology company against consumer fraud class actions involving smartphones
  • Representing the audit committee of multinational energy company in internal investigation into shareholder False Claims Act allegations